Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Maria Sabater-Lleal et al, published in JTH:
“This is a very complete review of a very important field, explaining how genome-wide analyses are unraveling the genetic architecture responsible for the levels of the main cellular and plasma factors that regulate coagulation and fibrinolysis.
The authors combine this with a brief look at global coagulation tests, all this in the context of how multiple gene variants influence venous and arterial thrombosis.
Step by step we are approaching the day when whole genome sequencing will become the norm and a prerequisite for personalized medicine.
In my own field of inherited platelet disorders and in particular Glanzmann thrombasthenia, the polygenic scores of gene variants either favoring or protecting from excessive and frequent mucocutaneous bleeding should help select patients most apt for gene therapy or to receive new generation long-term prophylaxis designed to upgrade fibrin formation at sites of bleeding.
For the latter, determining the therapy dose will be crucial in assuring safety.
This review is highly recommended for all in the coagulation and hemostasis fields.”
Title: Historical review: more than two decades understanding the genetic architecture of hemostasis and thrombosis
Authors: Maria Sabater-Lleal, Florian Thibord, Paul S de Vries, Jennifer Huffman, Alisa S Wolberg, Charles J Lowenstein, Alanna C Morrison, Andrew D Johnson, Nicholas L Smith
Read the Full Article on JTH
Other articles featuring Alan Nurden on Hemostasis Today.
-
Aug 14, 2026, 13:43Edward Lee Carter: Optimizing Anticoagulation in Cirrhosis Beyond the Lab Numbers
-
Aug 14, 2026, 13:39Amr Saad: What Tips You Toward Cerebral Venous Thrombosis Over IIH?
-
Aug 14, 2026, 13:28Eduardo Medronha: DIPS as a Rescue Strategy in Budd–Chiari Syndrome
-
Aug 14, 2026, 13:18Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
-
Aug 14, 2026, 13:04Mohammed M. Aboudeif: Cerebral Venous Thrombosis – Think Early, Treat Decisively
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma